|
| |
Email:
TDBarrett1@gmail.com
Nationality: Canadian citizen.
Work status: Permanent Resident in the USA.
EDUCATION
Postdoctoral fellow. Department of Pharmacology, University of Michigan, Ann
Arbor, Michigan, USA. 2001. Advisor: Professor Benedict R. Lucchesi.
Ph.D., Pharmacology. University of British Columbia Vancouver BC CANADA.
Thesis: “Relationship between ischaemia-selective drug action and
antiarrhythmic efficacy.” 1999. Advisor: Professor Michael J.A. Walker.
Baccalaureate of Science in Pharmacology. University of British Columbia
Vancouver BC CANADA. 1993. First Class degree.
EMPLOYMENT HISTORY
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
San Diego, CA, USA
Principal Scientist: present
Senior Scientist: 3/03 to 3/07
Scientist: 4/01-3/03
• I lead an in vivo pharmacology group reporting to Nigel Shankley. My team
has 6 direct reports and specializes in whole animal pharmacology, PK/PD and
the use of pharmacologically relevant animal models of human disease to
select and characterize the actions of new medical entities (NMEs).
• I am a drug discovery project leader responsible for directing the
activities of 10 full time employees in a highly matrixed environment. The
program is the anemia/cardiovascular/metabolic area.
• I was an active team member on programs resulting in 4 new medical
entities (NMEs) in three different therapeutic areas (gastro-intestinal,
anemia & cardiovascular) in 6 years. During this time I had increasing
responsibility for pre-clinical pharmacology, safety pharmacology and
toxicology for these programs. One of these NMEs is in Phase I and the
second is at a clinical proof of concept stage (Phase Ib/IIa). I also
contribute to clinical protocol design and have oversight for the PKPD/bio-marker
aspects of experimental medicine for the team’s clinical stage programs.
Terry Barrett, Ph.D.
Phone 760-221-2911
• I am responsible for capital purchases for the team and am active in
recruiting for the site (10-20 hiring committees per year).
• I have been a voting member on the Institutional Use and Care of Animals
committee for >4 years.
• Finally I have been included as an in-licensing team member from small
molecule therapeutics for Johnson & Johnson.
Nortran Pharmaceuticals, Inc. Now Cardiome Pharma Corp.
Vancouver, British Columbia, CANADA
May 1998 - June 1999
September1995-May 1998. Natural Sciences and Engineering Research Council
Industry/ Nortran Pharmaceuticals industry co-sponsored studentship.
• I contributed to the discovery of a novel anti-arrhythmic drug currently
being considered by the FDA for the treatment of atrial fibrillation
(RSD1235, now called vernakalant hydrochloride or KYNAPID™) while working at
Nortran. As part of this work I provided critical proof of concept
pre-clinical studies for the companies approach to the treatment of
ventricular and atrial arrhythmias. The FDA advisory panel recently voted
6-2 in support of approving KYNAPID™ for the treatment of atrial
fibrillation. A decision from the FDA is expected Jan. 19th, 2008.
• During this time, I had the opportunity to participate in out-licensing
and collaborative research programs with major pharmaceutical companies.
Ciba-Geigy AG, Basel SWITZERLAND
Summer student
May 1993-Oct. 1993
PROFESSIONAL ACTIVITIES
Adjunct Professor. Department of Anesthesiology, Pharmacology &
Therapeutics, Faculty of Medicine. University of British Columbia,
Vancouver, British Columbia, CANADA. 2003-present.
Sponsor for Department of Pharmacology & Therapeutics co-op students.
Invited referee for British Journal of Pharmacology, European Journal of
Pharmacology, Cardiovascular Research, Gut, Life Sciences & Journal of
Pharmacological & Toxicological Methods.
Member of the Pharmacological Society of Canada, Western Pharmacology
Society, American Society for Experimental Pharmacology and Therapeutics and
the American Heart Association. 2
Terry Barrett, Ph.D.
Phone 760-221-2911
PEER REVIEWED PUBLICATIONS
T.T. Hong, J. Huang, T.D. Barrett & B.R. Lucchesi. (2008). Effects of
cyclooxygenase inhibition on canine coronary artery blood flow and
thrombosis. Am J Physiol Heart Circ Physiol. 294: H145-155.
C.R. Woods, M.D. Hack, B.D. Allison, V.K. Phuong, M.D. Rosen, M.F. Morton,
C.E. Prendergast, T.D. Barrett, N.P. Shankley & M.H. Rabinowitz. (2007).
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2
ligands. Bioorg Med Chem Lett. 2007 Sep 29
L. Gomez, M.D. Hack, K. McClure, C. Sehon, L. Huang, M. Morton, L. Li, T.D.
Barrett, N. Shankley & J.G. Breitenbucher. (2007). SAR studies of
1,5-diarylpyrazole-based CCK1 receptor antagonists. Bioorg Med Chem Lett.
17: 6493-6498.
M.F. Morton, T.B. Barrett, W. Yan, J.M. Freedman, G. Lagaud, C.E.
Prendergast, V. Moreno, J. Pyati, K. Figueroa, L. Li, W. Wu, M. Rizzolio,
J.G. Breitenbucher, K. McClure & N.P. Shankley. (2007).
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate
(JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor
antagonist: in vitro and in vivo pharmacological comparison with
dexloxiglumide. J Pharmacol Exp Ther. 323: 562-569.
B. Plouvier, G.N. Beatch, G.L. Jung, A. Zolotoy, T. Sheng, L. Clohs, T.D.
Barrett, D. Fedida, W.Q. Wang, J.J. Zhu, Y. Liu, S. Abraham, L. Lynn, Y.
Dong, R.A. Wall & M.J. Walker. (2007). Synthesis and biological studies of
novel 2-aminoalkylethers as potential antiarrhythmic agents for the
conversion of atrial fibrillation. J Med Chem. 50(12): 2818-2841.
G.J. Lagaud, A. Young, A. Acen, M.F. Morton, T.D. Barrett & N.P. Shankley.
(2007). Obestatin reduces food intake and suppresses body weight gain in
rodents. Biochem Biophys Res Commun. 357(1): 264-269.
B.D. Allison, V.K. Phuong, L.C. McAtee, M. Rosen, M. Morton, C. Prendergast,
T. Barrett, G. Lagaud, J. Freedman, L. Li, X. Wu, H. Venkatesan, M. Pippel,
C. Woods, M.C. Rizzolio, M. Hack, K. Hoey, X. Deng, C. King, N.P. Shankley &
M.H. Rabinowitz. (2006). Identification and optimization of anthranilic
sulfonamides as novel, selective cholecystokinin-2 receptor antagonists. J
Med Chem. 49(21): 6371-6390.
J.K. Hennan, E.M. Driscoll, T.D. Barrett, P.S. Fischbach & B.R. Lucchesi.
(2006). Effect of sodium/hydrogen exchange inhibition on myocardial infarct
size after coronary artery thrombosis and thrombolysis. Pharmacology. 78(1):
27-37.
J.M. Freedman, T.D. Barrett & N.P. Shankley. (2006). A novel, quantitative
bio-assay for cholecystokinin type-1 receptor activity in the anaesthetised
rat. J Pharmacol Toxicol Methods. 54(1): 36-41.
3
Terry Barrett, Ph.D.
Phone 760-221-2911
C. Sehon, K. McClure, H. Hack, M. Morton, L. Gomez, L. Li, T.D. Barrett, N.
Shankley & J.G. Breitenbucher. (2006). Pyrazole CCK(1) receptor antagonists.
Part 2: SAR studies by solid-phase library synthesis and determination of
Free-Wilson additivity. Bioorg Med Chem Lett. 16(1): 77-80.
K. McClure, M. Hack, L. Huang, C. Sehon, M. Morton, L. Li, T.D. Barrett, N.
Shankley & J.G. Breitenbucher. (2006). Pyrazole CCK(1) receptor antagonists.
Part 1: Solution-phase library synthesis and determination of Free-Wilson
additivity. Bioorg Med Chem Lett. 16(1): 72-76.
T.D. Barrett, D.J. Triggle, M.J.A. Walker & D.H Maurice. (2005). Mechanism
of tissue-selective drug action in the cardiovascular system. Mol.
Interventions. 5(2): 84-93.
M.J.A. Walker, T.D. Barrett & L.J. Guppy. (2004). Functional pharmacology:
the drug discovery bottleneck? (Reductionism plus functionalism). Drug
Discovery Today. 3: 208-215.
P.S. Fischbach, A. White, T.D. Barrett & B.R Lucchesi. (2004). Risk of
ventricular proarrhythmia with selective opening of the myocardial
sarcolemmal versus mitochondrial ATP-gated potassium channel. J. Pharmacol.
Exp. Ther. 309(2): 554-559.
G. Sarraf, T.D. Barrett & M.J.A. Walker. (2003). Tedisamil and lidocaine
enhance each other’s antiarrhythmic activity against ischaemia-induced
arrhythmias in rats. Br. J. Pharmacol. 139(8): 1389-1398.
P.S. Fischbach, T.D. Barrett, N.J. Reed & B.R. Lucchesi. (2003).
SNC-80-induced Preconditioning: Selective Activation of the Mitochondrial
Adenosine Triphosphate-gated Potassium Channel. J. Cardiovasc. Pharmacol.
41(5): 744-750.
T.D. Barrett, J.K. Hennan, R.M. Marks & B.R. Lucchesi. (2002). C-Reactive
protein associated increase in myocardial infarct size after
ischemia/reperfusion. J. Pharmacol. Exp. Ther. 303(3): 1007-1013.
G.N. Beatch, T.D. Barrett, B. Plouvier, G. Jung, R.A. Wall, A. Zolotoy &
M.J.A. Walker. (2002). Ventricular fibrillation, an uncontrolled arrhythmias
seeking new targets. Drug Dev. Res. 55: 45-52.
P.S. Fischbach, T.D. Barrett, R. Goyal, B.C. Tran, Z. A. Syed, J.K. Hennan &
B.R. Lucchesi. (2001). Conversion of atrial fibrillation by the experimental
antiarrhythmic drug tedisamil in two canine models. J. Cardiovasc.
Electrophysiol. 12(10): 1138-1144.
J.K. Hennan, J. Huang, T.D. Barrett, E.M. Driscoll, D.E. Willens, A.M. Park,
L.J. Crofford & B.R. Lucchesi. (2001). Effects of selective cyclooxygenase-2
inhibition on vascular responses and thrombosis in canine coronary arteries.
Circulation. 104(7): 820-825.
4
Terry Barrett, Ph.D.
Phone 760-221-2911
5
T.D. Barrett, J.K. Hennan, E.M. Driscoll Jr., P.S. Fischbach, B.P. O’Neill &
B.R. Lucchesi. (2001). Tedisamil and dofetilide-induced torsades de pointes;
rate and potassium dependence. Br. J. Pharmacol. 132(7): 1493-1500.
T.D. Barrett, B.A. MacLeod & M.J.A. Walker. (2000). RSD1019 suppresses
ischaemia-induced monophasic action potential shortening and arrhythmias in
anaesthetised rabbits. Br. J. Pharmacol. 131(3): 405-414.
T.D. Barrett, S. Abraham, E.S. Hayes, S.L. Yong, & M.J.A. Walker. (2000).
Lack of ischaemia selectivity for Class I antiarrhythmic drugs limits their
antiarrhythmic effectiveness. Eur. J. Pharmacol. 398(3): 365-374.
T.D. Barrett & M.J.A. Walker. (1998). Glibenclamide does not prevent action
potential shortening induced by ischemia in anesthetized rabbits but reduces
ischemia-induced arrhythmias. J. Mol. Cell. Cardiol. 30(5): 999-1008.
A.I. Bain, T.D. Barrett, G.N. Beatch, D. Fedida, E.S. Hayes, B. Plouvier,
M.K. Pugsley, M.J.A. Walker, M.L. Walker, R.A. Wall, S.L. Yong & A. Zolotoy.
(1997). Better antiarrhythmics? The development of antiarrhythmic drugs
selective for ischaemia dependent arrhythmias. Drug Dev. Res. 42: 198-210.
T.D. Barrett, B.A. MacLeod & M.J.A. Walker. (1997). A model of myocardial
ischaemia for the simultaneous assessment of electrophysiological changes
and arrhythmias in intact rabbits. J. Pharmacol. Toxicol. Meth. 37(1):
27-36.
E.S. Hayes, T.D. Barrett, D. Burrill & M.J.A. Walker. (1996). Effects of
halothane and isoflurane on rat ventricular action potentials recorded in
situ. Life Sciences 58(16): 1375-1385.
T.D. Barrett, E.S. Hayes & M.J.A. Walker. (1995). Lack of selectivity for
ventricular and ischaemic tissue limits the antiarrhythmic actions of
lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias.
Eur. J. Pharmacol. 285(3): 229-238.
PATENTS
T.D. Barrett, J.G. Breitenbucher, L. Gomez, M.D. Hack, L. Huang, K.J.
McClure, M.F. Morton, C.A. Sehon & N.P. Shankley. Preparation of
3-(1H-pyrazol-3-yl)propionates as CCK-1 receptor modulators. PCT Int. Appl.
(2004), 326 pp. CODEN: PIXXD2 WO 2004007463 A1 20040122 CAN 140:128414 AN
2004:60479.
A.J.W. Hsueh, S.Y.T. Hsu, T.D. Barrett, M.F. Morton, C. Prendergast & N.P.
Shankley. Cosmedian, cospeptin and their uses. Provisional patent. (2004). |
|
